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Commentary by Hoosen Coovadia
a n dR u t hM .B l a n d
The concurrence of the two major epidemics of HIV
and tuberculosis in many parts of the world has
had a major impact on child health and survival
(1,2), reversing signiﬁcant advances in promoting
child health programmes in the southern African
region. The HIV epidemic is pivotal in contributing
to these losses, and tuberculosis is recognized as one
of the most common opportunisitic infections (3–6).
In South Africa the plight of infants and children
has worsened because of the impact of a number of
colliding health epidemics, considered characteristic
of poverty and wealth, on this age group (including
maternal, newborn and child diseases; HIV/TB; non-
communicable diseases; and violence and crime) (7).
Considerable progress in paediatric HIV has been
made since 1994 when antiretroviral drugs were ﬁrst
shown to reduce transmission of HIV from mothers
to their infants (8,9). Treatment of HIV-infected chil-
dren has since been successfully introduced in many
developing countries (10,11). The current priorities in
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these countries are to increase coverage and improve
the quality of health services. The increasing burden
of tuberculosis in children pari passu with that of
HIV, however, has not attracted the same degree of
attention, despite the fact that co-infection with tuber-
culosis is a very serious disease. In comparison with
HIV-uninfected children, tuberculosis in HIV-infected
children is more readily acquired but more difﬁcult
to diagnose; has a higher incidence; disease is severe,
with more rapid progression to death, higher mortal-
ity rates, lower cure rates and more frequent recur-
rences; and treatment is complicated by adverse drug
interactions (2).
The review by Gray, Zar and Cotton, is therefore
particularly pertinent. The review describes the search
for evidence of the beneﬁt of INH prophylaxis in HIV-
infected children. A stark reminder of the paucity of
reliable data on this subject is that only one trial met
their selection criteria.
The objectives of the study are well deﬁned,
and the search strategy was comprehensive, cover-
ing recognized web-based databases, manual searches
for articles, and consultation with experts. They
included studies of ‘HIV-infected children randomized
to receive either tuberculosis prophylaxis or placebo,
or an alternative TB preventive regimen’. One of
the authors and an independent individual undertook
the data extraction from the single study included in
the review. The key question is whether the recom-
mendations from the review are clinically useful and
of public health importance. The authors conclude
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that ‘isoniazid prophylaxis has a substantial protec-
tive effect on TB incidence and death in HIV-infected
children not on HAART’. The authors are rightly more
circumspect in recommending ‘isoniazid prophylaxis
in HIV-infected children has the potential to play a
major public health role by reducing TB incidence
and death’. The reason for their caution is not that
there may be limitations to interpretation of the data
from their single study, but because of untested issues
including relevance of the ﬁndings to areas of low
tuberculosis prevalence, absence of data on INH for
children on HAART, and lack of clarity on the dura-
tion of INH prophylaxis.
The study has many strengths: it was well con-
ducted; the design was appropriate; the diagnostic cri-
teria, always difﬁcult in children and more so when
there is coinfection with HIV, are standard; the authors
are among the leading ﬁgures in childhood tubercu-
losis; and the environment of their study has been
extensively researched over many years. The statisti-
cal planning to determine sample size and the ﬁndings
on efﬁcacy, safety and tolerability are convincing.
What, if any, are the limitations? These are pri-
marily because of the restricted applicability of the
ﬁndings. There are different views on the number of
studies required to initiate or change policy. Given the
multiple variations in populations and their environ-
ments, it is prudent to expect divergent results from
a range of settings. There were a number of publi-
cations from across continents on the use of Vitamin
A prophylaxis to reduce child mortality and morbid-
ity, which ﬁnally led to introduction at national level
(12). In contrast, the demonstration that antiretroviral
drugs substantially reduced mother-to-child transmis-
sion in one study from the developed world changed
practices in most countries (8). However, the regimen
used to achieve decreased transmission in developing
countries differed markedly from the original protocol
of the US/French study (13,14). The authors of this
review allude to the distinctive features at the study
site, which should be considered before accepting any
recommendation on INH prophylaxis for HIV-infected
children. In summary these include: the extremely high
tuberculosis incidence, one of the highest in the world;
the relatively high socio-economic status of the popu-
lation compared to the rest of South Africa; the supe-
rior health facilities compared to other provinces in the
country; and background diseases such as alcoholism
which are a dominant part of the proﬁle of diseases.
Some minor points also require clariﬁcation, includ-
ing: the effect of prior BCG vaccination; the propor-
tion of children with ‘probable’ and ‘deﬁnite’ tubercu-
losis among those who became infected, and speciﬁ-
cally whether the sensitivity of the deﬁnition of ‘proba-
ble’ cases affects the outcomes; the causes of mortality
in the two study arms; and some discussion of the
importance of determining whether INH prophylaxis
is efﬁcacious in HIV-exposed but uninfected infants,
and when treatment in these infants should be started.
This latter group of infants is increasingly relevant
as Prevention of Mother-to-Child transmission pro-
grammes are implemented and vertical transmission
is reduced. It would be useful to know if there are any
published accounts of the study cohort 5 years after
the publication of the paper, and pertinent to discuss
the cost-beneﬁts of rolling-out INH prophylaxis to all
children, or whether it would be more effective to tar-
get certain groups of children, for example those living
in households with tuberculosis.
Published results of other trials are awaited. A recent
NIH funded study of INH prophylaxis in HIV-infected
and HIV-exposed but uninfected infants, conducted in
the Western Cape, Johannesburg and Durban, South
Africa, failed to demonstrate any protection against
incident tuberculosis in either of these two groups
(reported in a plenary presentation by S. Madhi at
the 1st International Workshop of Pediatrics, Cape
Town, 17–18 July 2009). The authors of this review
are cognizant of the need to restrict INH prophylaxis
to those who cannot access antiretroviral treatment.
The global effort to increase coverage will inevitably
lead to wider access to these drugs, a decrease in
tuberculosis incidence in those treated with HAART
(15), and probably discourage use of other prophylaxic
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C o m m e n t a r yb yT o n yW a l l s
Tuberculosis (TB) is a leading cause of HIV related
deaths worldwide. In 2007 the WHO estimated that
1.37 million new cases of TB occurred among HIV-
infected people with approximately 456,000 of them
dying. The use of antiretroviral therapy in children has
been found to reduce the probability of being diag-
nosed with TB by as much as 85%. Yet the majority
of children with HIV who require antiretroviral ther-
apy do not have access to it. Recent estimates suggest
that only around 30% of people in sub-Saharan Africa
who require antiretroviral therapy actually receive it.
While there are ongoing improvements in access to
HIV therapy in many regions, the proportion of chil-
dren who receive appropriate treatment is often still
well below the level in adults. There is therefore a
real need for simple interventions to prevent TB dis-
ease in children with HIV infection who are at high
risk of exposure to TB.
The use of isoniazid prophylaxis to prevent tubercu-
losis disease in patients with M. tuberculosis infection
is well established in both adults and children. Fol-
lowing TB infection, children – especially those less
than 2 years of age – are the most likely to develop
disease. They are also more likely to develop severe
disease such as miliary TB or TB meningitis. Hence,
it is children who are most likely to beneﬁt from any
intervention that reduces the development of TB dis-
ease. This Cochrane review addresses the question of
how effective isoniazid prophylaxis is for preventing
TB in children with HIV infection who are at high-risk
of TB exposure.
The major ﬁnding of the review is the lack of
research on the use of isoniazid prophylaxis in HIV
infected children. Only one study fulﬁlled the inclu-
sion criteria for review, and this was a random-
ized controlled trial conducted by two of the review
authors. They found signiﬁcant beneﬁts for children
on isonaizid prophylaxis both in terms of all-cause
mortality and development of TB. The improved sur-
vival is intriguing, as most of the deaths in the control
group did not appear to be TB-related. This raises the
possibility that the effect of isoniazid on survival may
be due to more than just its effect on M. tubercu-
losis. The rates of TB in the treatment group were
approximately half of those in the control group, and
importantly none of the children who developed TB
while on isoniazid prophylaxis had evidence of drug-
resistant organisms. It will be interesting to see if
these effects remain when longer term follow-up data
are available. Few of the children in this study were
on antiretroviral therapy, and it will be important to
establish if isoniazid prophylaxis has any additional
beneﬁt to antiretroviral therapy alone as the rollout
of antiretrovirals continues. Unfortunately the kind of
longitudinal data that are required to fully assess the
use of isoniazid for TB prophylaxis in HIV infected
children cannot be provided by this study alone. Areas
that still need evaluation include the effect of an inter-
vention such as this in regions of low TB prevalence,
and how the added pill burden affects compliance with
antiretroviral therapy.
One could question the editorial justiﬁcation for
publishing a review where only one paper fulﬁls the
criteria for inclusion, particularly when the review is
conducted by the authors of that paper. However, this
should not take away from the ﬁnding that on this
important topic more research is urgently required. It
is hoped that this review will act as a bookmark for
future reviews in the expectation that further quality
evidence will be obtained.
Those looking to read the principle paper from this
review should note that there is an error in the citation.
It is listed in the review as having been published in
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